Elon Musk Reveals Why He Needs So Much Control of SpaceX
Axe Cap view
SpaceX’s Long Game Comes with High Risk
Elon Musk’s tight control at SpaceX highlights a bet on distant rewards, but the journey is winding and pricey.
SpaceX’s market potential is undeniably massive, sitting on futuristic ideas like space data centers and Mars colonization that could redefine industries. But its volatile shares and heavy capital needs remind us that this isn’t a quick flip. Musk’s 80% voting control shows his insistence on steering the ship through uncertainty, which might be reassuring or off-putting depending on your trust in his vision. For South African investors, this story translates mostly to USD/ZAR risks. A weaker rand against the dollar could make any investment in such a US-based, tech-heavy play more expensive and volatile. Local parallels are scarce; none of our JSE giants carry the same space ambitions or burn rates. So, it’s really a gauge of appetite for long-term, patient risk through the rand-dollar channel. The biggest threat? Musk’s ambitions might be too big and slow to deliver profits, leaving patient capital tied up for years. this is just our opinion and not financial advice
Avoid jumping into SpaceX or similar US tech plays without a strong rand hedge. Instead, watch USD/ZAR closely—if the rand weakens further, funding such speculative offshore exposure gets costlier. Consider domestic counters with clearer cash flows like Naspers or MTN if you want tech exposure with better local footing.
- USD/ZAR
- Naspers
- MTN
- Extended unprofitability delaying returns
- Rand weakening against USD increasing cost of offshore investment
6/10
Elon Musk maintains 42% ownership and over 80% voting control of SpaceX to focus on long-term goals spanning 5-10 years, including space data centers and Mars missions. Despite a $28.5 trillion total addressable market outlined in its S-1 filing, SpaceX stock has proven volatile, dropping over 50% from June highs to below $109. The unprofitable company requires significant capital infusions, demanding patient investors willing to wait for long-term value realization.
Our take is based on reporting first published by The Motley Fool.